On Mar. 24, 2020, Bausch Health announced it had donated medicines and health care products to assist in the global fight against COVID-19 while also pursuing research to determine if products in their existing portfolio may offer valuable treatment option.

• n Europe, the Company is ramping up the manufacturing of chloroquine and azithromycin and is seeking emergency access in certain countries with the goal of donating these products where and when needed.
• In Italy, the Bausch Foundation is making available for donation its antiviral VIRAZOLE® (Ribavirin for Inhalation Solution, USP) for nebulization in compassionate use in Italian hospitals.
• In Spain, the Bausch Foundation is making available for donation ARTELAC® Splash™ eye drops for use in local hospitals.
• In the United States, the Company’s gastroenterology business Salix Pharmaceuticals is working with key opinion leaders to initiate investigative trials to evaluate XIFAXAN® (rifaximin) in combination with established therapies, supportive care and other investigative therapies to Ipotentially address the symptoms of gastrointestinal distress and pulmonary compromise associated with COVID-19 infection. If the trials demonstrate XIFAXAN is successful in resolving these symptoms or reducing the duration of COVID-19, the Bausch Foundation will donate XIFAXAN to various hospitals.
• In Wuhan, China, health care providers treating patients with COVID-19 reported that they were hindered by fogging eyeglasses while wearing protective gear, such as goggles, face masks and containment suits. The Company’s global eye health business Bausch + Lomb responded by donating Biotrue® ONEday daily disposable contact lenses to these health care providers.

In the U.S., the Company’s subsidiary Salix Pharmaceuticals was working to initiate investigative trials to evaluate XIFAXANﾮ (rifaximin) in combination with established therapies, supportive care and other investigative therapies to potentially address the symptoms of gastrointestinal distress and pulmonary compromise associated with COVID-19 infection.